

Previous Seminars

2019 – 2020

24 February

“Development of a priority-setting algorithm for vaccines: a discrete choice experiment”

Jeroen Luyten, Associate Professor of Health Economics at the Leuven Institute for Healthcare Policy at KU Leuven and a visiting fellow at the London School of Economics

3 February

“Augmented Medicine - The way Artificial Intelligence is reshaping clinical practice”

Giovanni Briganti, Associate Lecturer of Medical Technology (AI & Health) at ULB and Lecturer of Physiology at the ES Santé School of Health

20 January

“The economic cost of air pollution: Evidence from Europe”

Antoine Dechezleprêtre, Senior Economist at OECD

9 December

“Ethics, markets and organizations” (joint work with Jean Tirole)

Mathias Dewatripont, Co-director at I3h Institute and Professor at ULB, Former Executive Director of the National Bank of Belgium and Dean of the Solvay Brussels School of Economics and Management

25 November

A new year, a new you? A two-selves model of within-individual variation in food purchases

Bram De Rock, Professor in Mathematical Economics at ULB and KU Leuven; Director of ECARES

4 November

The importance of social network in health, health care and in health policies

Vincent Lorant, Professor at Faculty of Public Health, UCL

30 September

Vaccines hesitancy

Marie Neunez, Research fellow at I3h Institute

2018 – 2019

03 June

Effects of physician-industry interactions on treatments: the case of heart attacks

Sofia Amaral-Garcia, Postdoc Researcher at Hasselt University in the research group Economics and Public Policy

16 May

Opioid analgesics consumption in France

Ilaria Natali, Teaching Assistant for Advanced Industrial Organization, ULB

29 April

Market access of pharmaceutical innovation: international R&D, high prices and national competent authorities

Philippe Van Wilder, Professor in health economics and HTA at Ecole de Santé Publique, ULB

18 February

Subsidized Health Insurance and Healthcare Utilization: new evidence from a large-scale field experiment

Raf Van Gestel, Assistant Professor, Erasmus School of Economics & Erasmus School of Health Policy and Management

21 January

Therapeutic drug monitoring of biologics: where to start, where to end?

Lynda Grine, Doctor-assistant at Ghent University and Research Associate at the Dermatology Department of Ghent University Hospital

10 December

Scientific, regulatory, and economic challenges facing the implementation of phage therapy and the Belgian model

Bob Blasdel, Research Director for Vesale Pharma

30 November

The case of a multi-drug resistant infection

[Link to program](#)

26 November

Precision oncology: how to structure the continuum of clinical research into healthcare for rationale access to anti-cancer treatment

Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer

12 November

Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets

Georges Siotis, Associate Professor at the Economics Department of Universidad Carlos III de Madrid and CEPR Research Fellow

29 October

Towards new partnerships in the healthcare sector

Wim Van Haverbeke, Professor of Innovation Management & Strategy at the Hasselt University

08 October

Vaccines: how to value them, how to price them?

Michel Dewilde, MDWConsultant, former Senior Vice President R&D, Sanofi Pasteur

01 October

Measuring mortality in conflicts and disasters: why does it matter?

Debarati Guha, Director of the Centre for Research on the Epidemiology of Disasters (CRED) and Professor at the School of Public Health (UCL)